BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 16207256)

  • 1. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R; Chin P; Zhang M; Sies CW; Barclay ML
    Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
    Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
    Andoh A; Tsujikawa T; Ban H; Hashimoto T; Bamba S; Ogawa A; Sasaki M; Saito Y; Fujiyama Y
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
    Armstrong L; Sharif JA; Galloway P; McGrogan P; Bishop J; Russell RK
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1106-14. PubMed ID: 21929546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases.
    Schedel J; Gödde A; Schütz E; Bongartz TA; Lang B; Schölmerich J; Müller-Ladner U
    Ann N Y Acad Sci; 2006 Jun; 1069():477-91. PubMed ID: 16855176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel assay to improve therapeutic drug monitoring of thiopurines in inflammatory bowel disease.
    Vikingsson S; Andersson D; Almer S; Peterson C; Hindorf U
    J Crohns Colitis; 2014 Dec; 8(12):1702-9. PubMed ID: 25239576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.
    Winter JW; Gaffney D; Shapiro D; Spooner RJ; Marinaki AM; Sanderson JD; Mills PR
    Aliment Pharmacol Ther; 2007 May; 25(9):1069-77. PubMed ID: 17439508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
    Ansari A; Arenas M; Greenfield SM; Morris D; Lindsay J; Gilshenan K; Smith M; Lewis C; Marinaki A; Duley J; Sanderson J
    Aliment Pharmacol Ther; 2008 Oct; 28(8):973-83. PubMed ID: 18616518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
    Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
    Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis.
    Hindorf U; Jahed K; Bergquist A; Verbaan H; Prytz H; Wallerstedt S; Werner M; Olsson R; Björnsson E; Peterson C; Almer SH
    J Hepatol; 2010 Jan; 52(1):106-11. PubMed ID: 19906459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.